Acupath Laboratories Inc, a company involved in sub-specialised anatomic and molecular pathology services, has introduced its COVID-19 testing using the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit, it was reported on Friday.
The test results are available within 24 to 48 hours and this is one of the few labs focusing on regions of three coronavirus genes; orf-1ab, S protein, and N protein, and MS2 phage control.
John Cucci, chief sales officer, said, 'The timing of the launch of our test is crucial as new testing requirements were recently announced for patients scheduled for elective surgeries, as well as employees of nursing homes, rehab centres, assisted living facilities, and other healthcare entities.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT